Vaccine Testing and mRNA/RNA therapies
Support your vaccine development with in vivo immunogenicity testing, biodistribution studies, and in vitro immunoassays
As a preclinical contract research organization (CRO), InnoSer supports your vaccine development with in vivo immunogenicity testing, biodistribution studies, and in vitro immunoassays (cell-based assays, cytotoxicity). Different approaches can enhance the stability, safety, and efficiency of mRNA/RNA therapies.
InnoSer’s immunology experts offer customized study designs to determine vaccine safety and efficacy profiles. Optimization of delivery methods is crucial, as mRNA’s instability and negative charge require suitable carriers for in vivo delivery. Our team has a track record in supporting lipid nanoparticle and other delivery methods to improve mRNA vaccine safety and efficiency.
As a preclinical immunology CRO, InnoSer partners with you to navigate this complexity, focusing on innovative approaches, including LNPs for gene therapy. Nanoparticle-mediated delivery systems enhance mRNA vaccine stability, biocompatibility, and targeting, while also protecting mRNA molecules from degradation and enhance delivery to target cells and tissues, including the brain.
With flexible, fast study start times, you can accelerate your research. Outsourcing your preclinical vaccine and mRNA therapy studies to InnoSer gives you access to our comprehensive in vitro and in vivo immunology drug development portfolio, enhancing the precision and effectiveness of your therapeutic candidates.
Vaccine testing services & study types that InnoSer offers:
- Immunogenicity Studies
- Dose optimization studies
- Local and systemic Tolerance
- Pharmacokinetics and Pharmacodynamics (PK/PD) Studies
- Biodistribution studies
- Vaccine Efficacy in Disease Models
- Complementary in vitro immunoassays with cell lines or primary immune cell populations
Key readouts available during vaccine development:
- Tissue distribution and organ accumulation (BLI)
- Local and systemic tolerance: Clinical scoring, blood parameters, muscle thickness via calipers, histopathology
- Serum concentration, half-life, clearance, target engagement, and biomarkers
- Antibody titers, T-cell responses, cytokine profiles, and memory cells
- Dose-response curve, optimal dose, and safety
- Survival rate and immune protection correlates
- Cytokine levels (e.g., IL-2, IFN-γ, TNF-α) via ELISA or multiplex assays (MSD)
- Cell surface markers, intracellular cytokines, cell populations, immune cell activation status and polarization via flow cytometry
- Tissue damage and disease progression via histopathology
Example data featuring vaccine related readouts:
Representative image of vaccine biodistribution study
Following delivery of novel drug delivery vehicles for vaccine testing, the BLI signal allows to discriminate the distribution between the liver and spleen, providing real-time biodistribution and delivery information of novel therapeutic agents over time.
Related model options
Immunology Models Overview
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence.
DTH Mouse Model
Evaluate your compound’s immunomodulatory or immunosuppressive potential in the delayed-type hypersensitivity (DTH) mouse model.
IL-23 Induced Psoriasis Mouse Model
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute IL-23-Induced Psoriasis Mouse model.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Ready to work with a CRO that’s as committed as you are?
Join us in delivering impactful studies that bring therapies to patients sooner.
info@innoserlaboratories.com